Mperia Therapeutics Inc.
Industry
- Biotechnology
- Pharmaceuticals
See more in Biomedtracker
Latest on Mperia Therapeutics Inc.
Scrip
• By Deanna Kamienski, Beth Allan, Maureen Riordan, Steven Muntner, and Joseph Haas
Merck & Co. Inc. ’s Kim Folander believes collaboration between big pharma and academic or institutional researchers may take on an increasingly important role in pipeline expansion as the competitio
Scrip
• By Deanna Kamienski, Beth Allan, Maureen Riordan, and Steven Muntner
Advantagene Closes $14.2m Series A Round Immuno-oncology firm Advantagene Inc. raised $14.2m through the sale of its Series A convertible preferred shares to undisclosed investors. National Securi
Scrip
• By Deanna Kamienski
Biopharma start-ups brought in half as much funding in the third quarter as in the second quarter, but the number of alliances for new and emerging therapeutics firms stayed the same. Big pharma made